In 2015, Ma et al. investigated the efficacy of CIK cells armed with the bispecific antibody anti-CD3 x anti-EGFR (EGFRBi-Ab) to target EGFR-positive glioblastoma in vitro and vivo. The gene discussed is EGFR; the disease is glioblastoma.